Based on the real fundamentals though (not my warm fuzzy feelings about them), which includes a ultra high growth rate of 80% (which continues to accelerate indicating very strong momentum), run rate of $28m, high gross margins and rapidly improving bottom line, strong cash position etc, the actual "fair value" is closer to $1 imo, considering the valuation multiples of peer companies during their growth stages (discounted for the ASX market of course)
Ridiculously undervalued, hopefully the results later this month rectify this significant mispricing of the company.
CMS Proposes Major Increase in Reimbursement for Canaloplasty, page-459
-
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
21.3¢ |
Change
-0.008(3.41%) |
Mkt cap ! $48.67M | |||
| Open | High | Low | Value | Volume |
| 22.5¢ | 22.5¢ | 21.0¢ | $50.23K | 232.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 400905 | 21.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.5¢ | 51400 | 2 |
View Market Depth
| Last trade - 13.15pm 13/08/2024 (20 minute delay) ? |
| EYE (ASX) Chart |